This Solicitation opportunity from Government of Canada was posted on December 23, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Pralidoxime

Closed

W6369-26-A033International

Submission Closed01/22/2026, 07:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

DIBBS

ZINC OXIDE OINTMENTThe contract solicitation seeks zinc oxide ointment under NSN 6505-00-150-1990 with a requested quantity of five units, issued by the Defense Logistics Agency within the Department of Defense. The solicitation, identified by number SPE2DP-26-T-4279, was posted on July 26, 2026, and requires responses no later than August 3, 2026, with all deliveries expected to fulfill federal procurement requirements. No specific set-aside provisions or NAICS codes are designated, indicating open competition among qualified suppliers. The place of performance and point of contact details are not provided, and all further inquiries must be directed through the official DIBBS portal linked in the posting.

Defense Logistics Agency

POSTED

DEADLINE

Liquid Amies Transport Swab (ESWAB) SupplyThe contract is for the supply of ESWAB, Liquid Amies transport swabs with part number 480CFA, intended for the collection and transport of clinical specimens. This subcontract is issued under the Health and Human Services Commission in Texas and aligns with NAICS code 325412, indicating classification within pharmaceutical and medicine manufacturing. The solicitation was posted on July 24, 2026, with a response deadline set for August 18, 2026, at 4:30 PM. The swabs are critical for maintaining specimen integrity during transit and must meet specific clinical standards for accuracy and reliability. While the place of performance and point of contact details are not specified, the contract is accessible through the Texas SmartBuy portal for further procurement information.

Health and Human Services Commission

POSTED

DEADLINE

Radiopharmaceutical Manufacturing and RadiosynthesisThe contract outlines the GMP-compliant manufacturing of critical radiopharmaceuticals including Ga-68 DOTATATE, FDG, and Tc-99m based agents, requiring strict adherence to quality control protocols and regulatory standards throughout all production phases. The work must be performed at a facility in New Orleans with a zip code of 70119 and must include robust emergency continuity plans to ensure uninterrupted supply, particularly for time-sensitive diagnostic agents. Production processes must meet all applicable FDA and nuclear regulatory requirements with full documentation and traceability from raw materials to final product release. This is a subcontract under the Department of Veterans Affairs 256-NETWORK Contract Office 16, with a solicitation response deadline of August 8, 2026, and a posted date of July 24, 2026. The North American Industry Classification System code 325412 indicates a focus on pharmaceutical preparation manufacturing. The successful offeror must demonstrate proven capability in radiopharmaceutical radiosynthesis, validated quality assurance systems, and capacity to handle the unique logistical and safety challenges of radioisotope production. Continuous operational readiness and compliance with nuclear safety and transportation regulations are essential requirements.

256-NETWORK Contract Office 16 (36C256)

POSTED

DEADLINE

cDNA Clone & Molecular Biology SupplyThe contract pertains to the supply of cDNA clones encoding engineered antibody sequences for preclinical development, encompassing full molecular biology services from vector design through cloning and rigorous sequence validation. The work is required to deliver high-quality, accurately engineered genetic constructs that meet precise specifications for use in advancing therapeutic antibody candidates, ensuring reliability and reproducibility in downstream preclinical applications. All deliverables must be fully characterized and validated to confirm sequence fidelity and functional integrity. The solicitation, issued under the National Institutes of Health Office of Laboratory Animal Welfare within the Department of Health and Human Services, is a subcontract with a place of performance in Bethesda, Maryland, and carries the NAICS code 325412 for biological product manufacturing. Interested parties must submit responses by August 3, 2026, and the opportunity is open without specific set-aside classifications. The technical scope demands expertise in molecular cloning, antibody engineering, and quality control, with expectations for timely delivery and strict adherence to validated protocols to support rigorous preclinical timelines.

National Institutes Of Health Olao

POSTED

DEADLINE

Reagents and Consumables Supply for Microbiology TestingThe contract entails the ongoing supply of FDA-approved reagents, culture media, and consumables specifically designed for use with a microbiological identification and antimicrobial susceptibility testing system. All provided materials must comply with strict shelf-life requirements to ensure reliability and accuracy in diagnostic testing, and the supplier is obligated to support emergency deliveries to maintain uninterrupted laboratory operations. The work is to be performed at a designated location in Palo Alto, California, with all goods meeting federal regulatory standards for clinical diagnostic use. The contract is structured as a subcontract under the Department of Veterans Affairs through the 261-NETWORK Contract Office 21, and the North American Industry Classification System code 325412 indicates that it falls under pharmaceutical and medicine manufacturing. Bids are due by July 31, 2026, with the opportunity publicly posted on July 24, 2026, allowing qualified vendors to respond within the seven-day window.

261-NETWORK Contract Office 21 (36C261)

POSTED

DEADLINE

Radiopharmaceutical 5 yearThe U.S. Department of Veterans Affairs through the 256-NETWORK Contract Office 16 is conducting a sources sought synopsis to identify qualified vendors capable of providing radiopharmaceuticals to the Southeast Louisiana Veterans Health Care System in New Orleans, Louisiana. This is not a solicitation but a market research initiative to assess industry capabilities, business size classifications, and socioeconomic qualifications under NAICS code 325412, which has a size standard of 1,300 employees. Interested parties must submit a capability statement of five pages or less detailing their experience supplying radiopharmaceuticals to government or private medical facilities, including an authorized letter permitting such services. Responses must also include detailed information on business size, certification status under programs such as SDVOSB, VOSB, 8(a), HubZone, or woman-owned small business, UEI number, and SAM.gov registration status, with emphasis that future awards require active SAM registration and SBA certification for socioeconomic preferences. All submissions must be emailed to Veronica Maskell at veronica.maskell@va.gov with the subject line “Radiopharmaceuticals” no later than 2:00 PM CST on August 8, 2026. The response must not request a solicitation, as none currently exists; any future contract opportunity will be separately announced on GSA eBUY or Contract Opportunities, and vendors must respond to that formal solicitation to be considered for award. The Government will use responses to inform acquisition strategy and determine whether to proceed with a formal procurement. Proprietary information submitted will be protected in accordance with FAR 15.201(e), and respondents bear all costs associated with their submission. The place of performance is specified as New Orleans, LA, and the contract office is based in Ridgeland, MS, with the posting dated July 24, 2026. Failure to provide all requested information may result in the response being deemed inadequate for planning purposes.

256-NETWORK Contract Office 16 (36C256)

POSTED

DEADLINE

Chemical Agent Detector Refill Kit ManufacturingThe contract pertains to the manufacture of reactive chemical refill kits designed for use in military chemical agent detectors, encompassing the full scope of formulation, assembly, and packaging processes under strict hazardous material regulations. The work must adhere to established safety and compliance standards applicable to the handling and processing of chemically reactive substances, ensuring the kits are both effective and safe for deployment in military operations. The production environment must be certified and controlled to prevent contamination and to meet government-mandated protocols for hazardous goods. The subcontract is issued under the NAICS code 325412, indicating a focus on pharmaceutical and chemical manufacturing, and is managed by the Electrical Devices Division within the Department of Defense. Performance is required at an FPO address with ZIP code 96683, suggesting logistical coordination across military or overseas locations. The solicitation was posted on July 23, 2026, with proposals due by August 3, 2026, allowing a limited window for qualified vendors to respond. The contract does not specify a set-aside classification, and no point of contact information is provided in the solicitation, requiring potential bidders to navigate the DIBBS platform directly for further details.

ELECTRICAL DEVICES DIV

POSTED

DEADLINE

TEST STRIPS AND COLORThe contract specifies the procurement of urine test strips and color charts capable of detecting bilirubin, blood, glucose, ketone, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen, each packaged in bottles of 100 strips per unit, with a total quantity of two units required. The items must comply with stringent technical and quality requirements referenced from the DLA Master List of Technical and Quality Requirements and are subject to medical packaging standards, including compliance with Medical Marking Standard No. 1, which supersedes MIL-STD-129. Packaging must ensure protection against damage and safe delivery via common carriers at the lowest cost, with all labels clearly displaying the date of manufacture, expiration date, contract number, and lot number in accordance with MMS1C guidelines. A shelf-life requirement of 18 months is mandatory and non-extendable, with no more than two months allowed to have elapsed between the date of manufacture and the date of delivery to the government. The items are classified as a TYPE I (CODE K) item under the shelf-life specification, and all labeling must conform to the latest revision of MMS1C. The solicitation number is SPE2DS-26-T-263E, issued on July 23, 2026, with responses due by July 29, 2026, and delivery required within five days of award. The contracting office is under the Department of Defense’s Medical Supply Chain, with Mary-Kathryn Donahue designated as the primary point of contact. The NSN is 6550-01-221-5400, and the NAICS code is 325412, identifying the industry as medical and surgical instrument manufacturing.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

DEADLINE

ERYTHROMYCIN OPHTHALMIErythromycin Ophthalmic Ointment, USP, is a sterile topical medication containing 5 mg of erythromycin per gram in a base of mineral oil and white petrolatum, formulated for ophthalmic use as an RX-only product. Each unit is packaged in single-dose tubes containing 3.5 grams of ointment, with a unit of issue consisting of 24 tubes per package. The product has a total shelf life of 36 months, and upon receipt by the first government activity, it must have a minimum of 31 months of remaining shelf life. Storage requirements specify controlled room temperature between 15°C and 30°C (59°F–86°F), with protection from excessive heat and freezing. All packaging and labeling must strictly conform to Medical Marking Standard No. 1, superseding MIL-STD-129, and commercial packaging must comply with ASTM D3951 unless overridden by DLA’s Master List of Technical and Quality Requirements. The manufacturer is PADAGIS US LLC with NDC 00574-4024-39, and the NSN is 6505-01-189-7090. The contract requires delivery of one package (24 tubes) to Fort Bragg, North Carolina, within 20 days of issuance, with FOB destination and zero tolerance for quantity variance. Delivery must be made via traceable freight methods, excluding parcel post, and packaging must meet all DLA procurement standards including palletization and hazardous material handling per FED-STD-313 where applicable. The item falls under a Type I (Code Q) shelf-life category with a non-extendable 36-month lifespan. The contracting official must submit a referral via EBS to confirm product compliance with FDA regulations, including manufacturer and part number details. The solicitation, issued under SPE2DP-26-T-4260, was posted on July 23, 2026, with a response deadline of July 29, 2026, and the required delivery date is July 14, 2026. All documentation, labeling, and marking must align with DLA’s current technical and quality requirements, and the point of contact for inquiries is James McCullough.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

LORATADINE TABLETSLoratadine tablets 10 mg are being procured in quantities of 2 business units, with each unit containing 500 tablets, for a total of 1,000 tablets under contract SPE2DP-26-T-4248. The product must comply with all technical and quality requirements referenced in the DLA Master List of Technical and Quality Requirements, including packaging and marking standards specified in Medical Marking Standard No. 1, which replaces MIL-STD-129. Packaging must be commercial-grade, with each unit sealed in a container that protects against damage and breakage, and shipped in exterior containers suitable for safe delivery via common carrier at the lowest cost to the destination point. The item is regulated by the FDA and requires storage between 20°C and 25°C (68°F to 77°F), protected from excessive moisture. It has a non-extendable shelf life of 36 months, classified as a TYPE I (CODE Q) item under DLA shelf-life requirements. The manufacturer is OHM Laboratories Inc. with NDC 51660-0526-05, and the distributor is AmerisourceBergen Drug Corp. Delivery is FOB destination within 20 days of contract award with zero tolerance for quantity variance, and inspection and acceptance occur at the delivery point. The NSN is 6505-01-524-9179, and all markings must adhere to the latest MMS No. 1 guidelines available through DLA Troop Support. The contracting official must submit a referral in EBS with manufacturer and bidder details prior to award.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

DEXAMETHASONE TABLETSThe contract pertains to the procurement of Dexamethasone Tablets, USP, 0.5 mg, in unit dose packaging under the National Stock Number 6505-01-045-0451, with a total quantity of 2 packaging groups, each equivalent to 100 tablets. The supplier must adhere to strict packaging and labeling requirements as defined by Medical Marking Standard No. 1, which supersedes MIL-STD-129, and all units must be sealed in protective containers to ensure integrity during shipment. The product, manufactured by Roxane Labs or Hikma Pharmaceuticals USA Inc. under NDC 00054-8179-25, is regulated by the FDA and requires confirmation via EBS referral. It carries a non-extendable shelf life of 36 months and must be marked in full compliance with the latest Medical Marking Standard. Delivery is required FOB destination within five days of contract award, with zero variance allowed in quantity, and inspection and acceptance occur at the destination point. The solicitation is issued under SPE2DP-26-T-4266, with a response deadline of July 29, 2026, and the sole point of contact is James Foggie at DLA Troop Support, with performance directed to Fort Bragg, NC, 28310.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

TUBE, EXTENSION, INJEThe item is a 3-way stopcock extension set with 60-inch small bore tubing featuring a male luer lock connection, designed for injection procedures, with a priming volume of 1.3 mL and packaged in quantities of 25 units per package. The product is identified by NSN 6515-01-550-8492 and is being procured under solicitation SPE2DS-26-T-268C, with a response deadline of July 29, 2026, and a delivery requirement of 20 days after award. The specification includes technical and quality requirements referenced in the DLA Master List, and packaging must comply with DLA standards, including the removal of government identification from non-accepted supplies. The contract is managed by the Department of Defense through the Medical Supply Chain MD Surg FSF office, with performance required at Fort Bliss, Texas, and point of contact information provided for inquiries.

MEDICAL SUPPLY CHAIN MD SURG FSF

POSTED

3 days ago

DEADLINE

in 3 days

AI Contract Overview

The Department of National Defence, through its Strategic Medical Countermeasures Program and on behalf of the Canadian Forces Health Services Group, is seeking to procure Pralidoxime. This medication is intended for treating Canadian Armed Forces members who may have been exposed to chemical warfare agents. The contract initially requires the delivery of 1,025 doses by March 31, 2026, with an option to order up to an additional 4,100 doses between April 1, 2026, and March 31, 2030. There are no special security requirements for this procurement. This solicitation is open exclusively to Canadian suppliers and those from applicable trading partners, consistent with the policy on reciprocal procurement. The Crown maintains the right to negotiate with suppliers throughout the procurement process. Interested parties must submit their offers by January 22, 2026. The contract is managed by the Department of National Defence, and the point of contact for this procurement is Stephen Brown. Offers may be submitted in either of Canada’s official languages, and the place of performance is Canada, with worldwide delivery expected.

General Info

Department of National Defence seeks Pralidoxime supply: 1,025 doses by 2026, optional 4,100 doses later.

Agency

Government of Canada → Department of National DefenceView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

World, CAN

Set-Aside

NONE

Documents

(4)

Amendment 001 to Solicitation W6369-26-A033 Pralidoxime

PDF•2 pages•amendment

Amendment 001 to Solicitation W6369-26-A033 Pralidoxime

PDF•2 pages•amendment

RFP W6369-26-A033 Pralidoxime National Defence Canada

PDF•58 pages•rfp

RFP W6369-26-A033 Pralidoxime

PDF•55 pages•rfp

AI Contract Breakdown

Uniform Contract Format

Timeline

PhaseClosed

PostedDec 23

Solicitation

Response DeadlineJan 22

Deadline has passed

Submission Closed

01/22/2026, 07:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyGovernment of Canada → Department of National Defence

Contacts1 person available

OfficeN/A

Organization / Agency

Government of Canada → Department of National Defence

View Agency Profile

Office AddressN/A

Contacts

Stephen BrownContracting Authority

contact@example.gov

+1 (555) 000-0000

Full Description

The Department of National Defence (DND) through the Strategic Medical Countermeasures Program on behalf of the Canadian Forces Health Services Group, has a requirement for Pralidoxime for the treatment of Canadian Armed Forces (CAF) members suspected of exposure to chemical warfare agents. The initial requirement is for the delivery of 1,025 doses to be delivered before 31 March 2026. Optional requirements of 4,100 doses to be requested and delivered between 01 April 2026 and 31 March 2030. There are no security requirements associated with this requirement. The Crown retains the rights to negotiate with suppliers on any procurement. Documents may be submitted in either official language of Canada. Policy on Reciprocal Procurement: This solicitation of offers is open only to Canadian suppliers (if subject to any international trade agreement(s)): and to Suppliers of an applicable trading partner.